Leap Therapeutics, Inc.
LPTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $20 | $0 | $0 | $11 |
| Gross Profit | -$20 | $0 | $0 | -$10 |
| % Margin | -9,631.6% | – | – | -4,461.5% |
| R&D Expenses | $20 | $11 | $13 | $13 |
| G&A Expenses | $8 | $2 | $3 | $7 |
| SG&A Expenses | $8 | $2 | $3 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | -$20 | $5 | $0 | $13 |
| Operating Expenses | $8 | $17 | $16 | $35 |
| Operating Income | -$28 | -$17 | -$16 | -$45 |
| % Margin | -13,330.6% | – | – | -19,223.9% |
| Other Income/Exp. Net | $2 | $0 | $0 | $3 |
| Pre-Tax Income | -$26 | -$17 | -$15 | -$42 |
| Tax Expense | $0 | $0 | $0 | -$2 |
| Net Income | -$26 | -$17 | -$15 | -$40 |
| % Margin | -12,425.4% | – | – | -17,166.2% |
| EPS | -0.08 | -0.4 | -0.37 | -0.37 |
| % Growth | 80% | -8.1% | 0% | – |
| EPS Diluted | -0.08 | -0.4 | -0.37 | -0.37 |
| Weighted Avg Shares Out | 41 | 41 | 41 | 41 |
| Weighted Avg Shares Out Dil | 41 | 41 | 41 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $1 |
| EBITDA | -$25 | -$17 | -$15 | -$20 |
| % Margin | -12,049.8% | – | – | -8,629.5% |